Accéder au contenu
Merck

Visual impairment in an optineurin mouse model of primary open-angle glaucoma.

Neurobiology of aging (2015-03-31)
Henry C Tseng, Thorfinn T Riday, Celia McKee, Catherine E Braine, Howard Bomze, Ian Barak, Carrie Marean-Reardon, Simon W M John, Benjamin D Philpot, Michael D Ehlers
RÉSUMÉ

Primary open-angle glaucoma (POAG) is characterized by progressive neurodegeneration of retinal ganglion cells (RGCs). Why RGCs degenerate in low-pressure POAG remains poorly understood. To gain mechanistic insights, we developed a novel mouse model based on a mutation in human optineurin associated with hereditary, low-pressure POAG. This mouse improves the design and phenotype of currently available optineurin mice, which showed high global overexpression. Although both 18-month-old optineurin and nontransgenic control mice showed an age-related decrease in healthy axons and RGCs, the expression of mutant optineurin enhanced axonal degeneration and decreased RGC survival. Mouse visual function was determined using visual evoked potentials, which revealed specific visual impairment in contrast sensitivity. The E50K optineurin transgenic mouse described here exhibited clinical features of POAG and may be useful for mechanistic dissection of POAG and therapeutic development.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
p-Phenylenediamine, 98% (GC)
Sigma-Aldrich
p-Phenylenediamine, sublimed, ≥99%
Sigma-Aldrich
p-Phenylenediamine, ≥99.0% (GC/NT)